Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Arthur Amron
AddedFeb 19, 2024
UpdatedMay 31, 2026
Arthur Amron

Arthur Amron

Board Member, Mammoth Energy Services

CrunchbaseLinkedIn

Arthur Amron's Career

Mammoth Energy Services
Mammoth Energy Services

Oklahoma City, OK, US

Board Member· Board
Nephros
Nephros

South Orange, NJ, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Arthur Amron's Career

Mammoth Energy Services
Mammoth Energy Services
Public$120M1k2014Oklahoma City, OK, US
Board Member· Board

Leadership at Mammoth Energy Services

Arty StraehlaArty StraehlaCEO
Joseph M JacobsJoseph M JacobsBoard Member
Spencer ArmourSpencer ArmourBoard Member
Kenneth A Rubin \"Ken\"Kenneth A Rubin \"Ken\"Board Member
Jim PalmJim PalmBoard Member
Arthur SmithArthur SmithBoard Member
Nephros
Nephros
Public$11.2M271997South Orange, NJ, US
Board Member· Board

Leadership at Nephros

Alisa LaskAlisa LaskBoard Member
Robert BanksRobert BanksCEO
William FoxWilliam FoxBoard Member
Oliver SpandowOliver SpandowBoard Member

Similar to Nephros

NephrosantNephrosantSan Mateo, CA, USMedical Devicesest. 2017NephrosantSan Mateo, CA, US · est. 2017

NephroSant: Pioneering kidney health monitoring and early detection tools.

Series A · $16M27
Pure Life RenalPure Life RenalHollywood, FL, USDialysis, Healthcareest. 2013Pure Life RenalHollywood, FL, US · est. 2013

Pure Life Renal: A leading kidney dialysis service provider, partnering with nephrologists for clinic growth.

Series B · $21M52
Nephron PharmaceuticalsNephron PharmaceuticalsWest Columbia, SC, USCompounding, Medicationsest. 1937Nephron PharmaceuticalsWest Columbia, SC, US · est. 1937

Nephron: Global leader in generic respiratory medication manufacturing and 503B drug compounding.

Private Equity · $425M816
Pure H2o TechnologiesPure H2o TechnologiesNewark, NJ, USWater Purificationest. 1997Pure H2o TechnologiesNewark, NJ, US · est. 1997

Founded in 2000, Pure H2O Technologies, Inc. specializes in manufacturing water purification systems.

Seed · $350k30

People Similar to Arthur Amron

Jay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoYun SeokYun SeokBoard Member · KakaoSanjay Singh YadavSanjay Singh YadavBoard Member · Mammoth ResearchMichael HidaryMichael HidaryBoard Member · CityVest CapitalMark MealyMark MealyBoard Member · ARC Document Solutions